All In Biotech

Free tool

FAERS Monitor: Ogivri

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761074 or its brand name (Ogivri, Trastuzumab-Dkst). Reports on generic versions are filed under their own applications.

Reports

274

Serious

241

88% of reports

Hospitalization

92

Death reported

47

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death32
  • off label use30
  • diarrhoea21
  • chills18
  • disease progression18
  • dyspnoea18
  • back pain17
  • fatigue16
  • malaise15
  • nausea15
  • weight decreased14
  • arthralgia13
  • neutropenia13
  • vomiting13
  • hospitalisation12

Reports by year received

View as table
YearReports
20181
20191
202010
202146
202235
202364
202458
202530
202629

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,885 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chillsSignal1811.87.5168
disease progressionSignal1811.77.5166
neutropeniaSignal137.34.365
hospitalisationSignal126.03.445
back painSignal175.63.561
weight decreasedSignal143.82.327
deathSignal322.92.138
off label useSignal302.61.930
malaiseSignal152.61.614
diarrhoeaSignal212.51.718
dyspnoeaSignal182.41.614
arthralgiaSignal132.41.49
vomitingSignal132.11.27
fatigue161.61.03
nausea151.50.92

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.